Patents Assigned to Oncotherapy Science, Inc.
  • Publication number: 20130011933
    Abstract: Objective methods for detecting and diagnosing bladder cancer (BLC) are described herein. In one embodiment, the diagnostic method involves determining the expression level of a BLC-associated gene that discriminates between BLC cells and normal cells. The present invention further provides means for predicting and preventing bladder cancer metastasis using BLC-associated genes having unique altered expression patterns in bladder cancer cells with lymph-node metastasis. The present invention provides methods of screening for therapeutic agents useful in the treatment of bladder cancer, methods of treating bladder cancer and method for vaccinating a subject against bladder cancer. Specifically, the present application provides novel human genes C2093, B5860Ns and C6055s whose expression is markedly elevated in bladder cancers.
    Type: Application
    Filed: June 28, 2012
    Publication date: January 10, 2013
    Applicant: Oncotherapy Science, Inc.
    Inventors: Yusuke Nakamura, Toyomasa Katagiri, Shuichi Nakatsuru
  • Publication number: 20120328636
    Abstract: The present invention provides nonapeptides selected from peptides comprising the amino acid sequence of SEQ ID NO:2, 3, 5, 8, 11, or 12; nonapeptides or decapeptides selected from peptides comprising the amino acid sequence of SEQ ID NO:29, 30, 33, 34, 40, or 46; and peptides with cytotoxic T cell inducibility, in which one, two, or several amino acids are substituted or added to the above-mentioned amino acid sequences, as well as pharmaceuticals for treating or preventing tumors, where the pharmaceuticals comprise these peptides. The peptides of this invention can be used as vaccines.
    Type: Application
    Filed: June 12, 2012
    Publication date: December 27, 2012
    Applicant: Oncotherapy Science, Inc.
    Inventors: Hideaki Tahara, Satoshi Wada, Takuya Tsunoda
  • Publication number: 20120321649
    Abstract: The present invention provides peptides having an amino acid sequence as set forth in SEQ ID NO: 19, 22, 30, 34, 344, 358, 41, 44, 46, 48, 78, 376, 379, 80, 100, 101, 110, 111, 387, 112, 394, 114, 116, 117, 121, 395, 133, 135, 137, 426, 143, 147, 148, 149, 150, 152, 153, 154, 156, 160, 161, 162, 163, 166, 174, 178, 186, 194, 196, 202, 210, 213, 214, 217, 223, 227, 228, 233, 254, 271, 272 or 288, as well as peptides having the above-mentioned amino acid sequences in which 1, 2, or several (e.g., up to 5) amino acids are substituted, deleted, or added, provided the peptides possess cytotoxic T cell inducibility. The present invention also provides drugs for treating or preventing a disease associated with over-expression of the CDH3, EPHA4, ECT2, HIG2, INHBB, KIF20A, KNTC2, TTK and/or URLC10, e.g. cancers containing as an active ingredient one or more of these peptides. The peptides of the present invention find further utility as vaccines.
    Type: Application
    Filed: May 4, 2012
    Publication date: December 20, 2012
    Applicant: Oncotherapy Science, Inc.
    Inventors: Takuya Tsunoda, Ryuji Ohsawa, Sachiko Yoshimura
  • Publication number: 20120308590
    Abstract: Oligopeptides having cytotoxic T cell inducibility and suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines are described herein. Notable examples include oligopeptides having the amino acid sequence of SEQ ID NO: 1, 3, 5 or 6, wherein 1, 2, or several amino acids are optionally substituted, deleted, inserted or added so long as they retain the cytotoxic T cell inducibility of the original oligopeptides. Pharmaceutical formulations or “drugs” related to such oligopeptides suitable for treating or preventing cancers or tumors, as well as the post-operative recurrence thereof, are also described.
    Type: Application
    Filed: November 30, 2010
    Publication date: December 6, 2012
    Applicant: OncoTherapy Science, Inc.
    Inventors: Yasuharu Nishimura, Michiko Harao, Yusuke Tomita, Yusuke Nakamura, Takuya Tsunoda
  • Publication number: 20120294877
    Abstract: The present invention provides immunogenic peptides comprising the amino acid sequence of SEQ ID NO: 1, 2, 13, 32, and peptides comprising the above-mentioned amino acid sequences in which 1, 2, or several amino acids are substituted or added, and having cytotoxic T cell inducibility, and also provides drugs for treating or preventing tumors comprising these peptides. The peptides of this invention can be used as vaccines.
    Type: Application
    Filed: August 3, 2012
    Publication date: November 22, 2012
    Applicant: Oncotherapy Science, Inc.
    Inventors: Hideaki Tahara, Takuya Tsunoda, Masabumi Shibuya, Shuichi Nakatsuru
  • Publication number: 20120288514
    Abstract: The present invention provides peptides having an amino acid sequence as set forth in SEQ ID NO: 7, 8, 9, 10, 11, 12, 192, 195, 197, 209, 225, 226, 228, 230, 240, 241, 243, 244, 249, 253, 254 or 255, as well as peptides having the above-mentioned amino acid sequences in which 1, 2, or several amino acids are substituted, deleted, or added, wherein the peptides possess cytotoxic T cell inducibility. The present invention also provides drugs for treating or preventing a disease associated with the over-expression of MPHOSPH1 and/or DEPDC1, e.g. cancers, containing these peptides as an active ingredient. The peptides of the present invention can also be used as vaccines.
    Type: Application
    Filed: July 30, 2012
    Publication date: November 15, 2012
    Applicant: ONCOTHERAPY SCIENCE, INC.
    Inventors: Tomoaki Fujioka, Yusuke Nakamura, Takuya Tsunoda, Ryuji Osawa, Midori Shida
  • Publication number: 20120282286
    Abstract: The present invention provides peptides having an amino acid sequence as set forth in SEQ ID NO: 7, 8, 9, 10, 11, 12, 192, 195, 197, 209, 225, 226, 228, 230, 240, 241, 243, 244, 249, 253, 254 or 255, as well as peptides having the above-mentioned amino acid sequences in which 1, 2, or several amino acids are substituted, deleted, or added, wherein the peptides possess cytotoxic T cell inducibility. The present invention also provides drugs for treating or preventing a disease associated with the over-expression of MPHOSPH1 and/or DEPDC1, e.g. cancers, containing these peptides as an active ingredient. The peptides of the present invention can also be used as vaccines.
    Type: Application
    Filed: June 27, 2012
    Publication date: November 8, 2012
    Applicant: ONCOTHERAPY SCIENCE, INC.
    Inventors: Tomoaki Fujioka, Yusuke Nakamura, Takuya Tsunoda, Ryuji Osawa, Midori Shida
  • Patent number: 8257711
    Abstract: The present invention provides immunogenic peptides comprising the amino acid sequence of SEQ ID NO: 1, 2, 13, 32, and peptides comprising the above-mentioned amino acid sequences in which 1, 2, or several amino acids are substituted or added, and having cytotoxic T cell inducibility, and also provides drugs for treating or preventing tumors comprising these peptides. The peptides of this invention can be used as vaccines.
    Type: Grant
    Filed: March 3, 2011
    Date of Patent: September 4, 2012
    Assignee: Oncotherapy Science, Inc.
    Inventors: Hideaki Tahara, Takuya Tsunoda, Masabumi Shibuya, Shuichi Nakatsuru
  • Publication number: 20120214174
    Abstract: Herein disclosed are methods of identifying substances suitable for the treatment and prevention of cancer, particularly cancers associated with the overexpression of GALNT6 gene. Methods of the present invention use or target the binding between GALNT6 protein and MUC1 protein, and the glycosylation of MUC1 protein by GALNT6 protein as an index of cancer, particularly breast cancer.
    Type: Application
    Filed: August 19, 2010
    Publication date: August 23, 2012
    Applicant: OncoTherapy Science, Inc.
    Inventors: Toyomasa Katagiri, Yusuke Nakamura, Takuya Tsunoda
  • Publication number: 20120190628
    Abstract: The present application provides novel human genes RNF43 whose expression is markedly elevated in colorectal cancers, as well as CXADRL1 and GCUD1 whose expression is markedly elevated in gastric cancers compared to corresponding non-cancerous tissues. The genes and polypeptides encoded by the genes can be used, for example, in the diagnosis of a cell proliferative disease, and as target molecules for developing drugs against the disease.
    Type: Application
    Filed: October 22, 2010
    Publication date: July 26, 2012
    Applicant: Oncotherapy Science, Inc.
    Inventors: Yusuke Nakamura, Yoichi Furukawa, Hideaki Tahara, Takuya Tsunoda
  • Patent number: 8221751
    Abstract: The present invention relates to an antibody or a fragment thereof which is capable of binding to a Frizzled homologue 10 (FZD10) protein, such as a mouse monoclonal antibody, a chimeric antibody and a humanized antibody. Also, the present invention relates to a method for treating and/or preventing FZD10-associated disease; a method for diagnosis or prognosis of FZD10-associated disease; and a method for in vivo imaging of FZD10 in a subject.
    Type: Grant
    Filed: August 24, 2006
    Date of Patent: July 17, 2012
    Assignee: Oncotherapy Science, Inc.
    Inventors: Yusuke Nakamura, Toyomasa Katagiri, Shuichi Nakatsuru, Keigo Endo, Motoki Kuhara, Kasumi Yagi
  • Patent number: 8206719
    Abstract: The present invention provides nonapeptides selected from peptides comprising the amino acid sequence of SEQ ID NO:2, 3, 5, 8, 11, or 12; nonapeptides or decapeptides selected from peptides comprising the amino acid sequence of SEQ ID NO:29, 30, 33, 34, 40, or 46; and peptides with cytotoxic T cell inducibility, in which one, two, or several amino acids are substituted or added to the above-mentioned amino acid sequences, as well as pharmaceuticals for treating or preventing tumors, where the pharmaceuticals comprise these peptides. The peptides of this invention can be used as vaccines.
    Type: Grant
    Filed: February 23, 2010
    Date of Patent: June 26, 2012
    Assignee: Oncotherapy Science, Inc.
    Inventors: Hideaki Tahara, Satoshi Wada, Takuya Tsunoda
  • Publication number: 20120156233
    Abstract: The present invention provides novel pharmaceutical agents and methods for treating or preventing diseases caused by neovascularization in human choroid (neovascular maculopathy). The present invention provides pharmaceutical compositions and vaccines for treating and/or preventing diseases caused by neovascularization in human choroid (neovascular maculopathy), comprising at least one type each of a peptide comprising an amino acid sequence derived from a VEGFR-1 protein and having an activity of inducing cytotoxic T cells, and a peptide comprising an amino acid sequence derived from a VEGFR-2 protein and having an activity of inducing cytotoxic T cells.
    Type: Application
    Filed: June 10, 2010
    Publication date: June 21, 2012
    Applicant: OncoTherapy Science, Inc.
    Inventors: Motokazu Tsujikawa, Yusuke Nakamura, Takuya Tsunoda
  • Publication number: 20120156231
    Abstract: The present invention provides isolated peptides having the amino acid sequence of SEQ ID NO: 34 or fragments thereof, which bind to HLA antigen and induce cytotoxic T lymphocyte (CTL). The present invention further provides peptides which include one, two, or several amino acid insertions, substitution or addition to the aforementioned peptides or fragments, but still have the cytotoxic T cell inducibility. Further provided are nucleic acids encoding any of these aforementioned peptides as well as pharmaceutical substances or compositions including any of the aforementioned peptides or nucleic acids. The peptides, nucleic acids, pharmaceutical substances or compositions of the present invention may be used for treating cancer or tumor.
    Type: Application
    Filed: February 17, 2010
    Publication date: June 21, 2012
    Applicant: Oncotherapy Science, Inc.
    Inventors: Takuya Tsunoda, Ryuji Ohsawa, Sachiko Yoshimura, Tomohisa Watanabe
  • Publication number: 20120149762
    Abstract: The present invention provides a novel human gene ZNFN3A1 whose expression is markedly elevated in a great majority of HCCs compared to corresponding non-cancerous liver tissues. The gene encodes a protein having a zinc finger domain as well as a SET domain and has been found to form a regulatory complex with RNA helicase and RNA polymerase.
    Type: Application
    Filed: February 23, 2012
    Publication date: June 14, 2012
    Applicant: Oncotherapy Science, Inc.
    Inventors: Yusuke Nakamura, Yoichi Furukawa
  • Publication number: 20120135020
    Abstract: Peptide vaccines against cancer are described herein. In particular, epitope peptides derived from the TTK gene that elicit CTLs are provided. Antigen-presenting cells and isolated CTLs that target such peptides, as well as methods for inducing the antigen-presenting cell, or CTL are also provided. The present invention further provides pharmaceutical compositions containing as active ingredients peptides derived from TTK or polynucleotides encoding the peptides. Furthermore, the present invention provides methods for the treatment and/or prophylaxis (i.e., prevention) of cancers (tumors), and/or the prevention of postoperative recurrence thereof, as well as methods for inducing CTLs, methods for inducing anti-tumor immunity, using the peptides derived from TTK, polynucleotides encoding the peptides, or antigen-presenting cells presenting the peptides, or the pharmaceutical compositions of the present invention.
    Type: Application
    Filed: May 10, 2010
    Publication date: May 31, 2012
    Applicant: OncoTherapy Science, Inc.
    Inventors: Yusuke Nakamura, Takuya Tsunoda, Ryuji Ohsawa, Sachiko Yoshimura, Tomohisa Wantanabe
  • Publication number: 20120128584
    Abstract: The present invention relates to anti-CDH3 antibodies, which can be labeled with a radioisotope. Moreover, the present invention provides methods and pharmaceutical compositions that comprise an anti-CDH3 antibody as an active ingredient. Since CDH3 is strongly expressed in pancreatic, lung, colon, prostate, breast, gastric or liver cancer cells, the present invention is useful in pancreatic, lung, colon, prostate, breast, gastric or liver cancer therapies.
    Type: Application
    Filed: June 30, 2009
    Publication date: May 24, 2012
    Applicant: Oncotherapy Science, Inc.
    Inventors: Akira Togashi, Masakazu Katsu, Megumi Takayanagi, Hiroki Yoshioka, Pohsing Ng, Yasuhiro Shiba, Yusuke Nakamura, Keigo Endo
  • Publication number: 20120128705
    Abstract: Peptide vaccines against cancer are described herein. In particular, epitope peptides derived from the C6orf167 gene that elicit CTLs are provided. Antigen-presenting cells and isolated CTLs that target such peptides, as well as methods for inducing the antigen-presenting cell, or CTL are also provided. The present invention further provides pharmaceutical compositions containing peptides derived from C6orf167 or polynucleotides encoding the polypeptides as active ingredients. Furthermore, the present invention provides methods for the treatment and/or prophylaxis of (i.e., preventing) cancers (tumors), and/or the prevention of postoperative recurrence thereof, as well as methods for inducing CTLs, methods for inducing anti-tumor immunity, using the peptides derived from C6orf167, polynucleotides encoding the peptides, or antigen-presenting cells presenting the peptides, or the pharmaceutical compositions of the present invention.
    Type: Application
    Filed: March 31, 2010
    Publication date: May 24, 2012
    Applicant: OncoTherapy Science, Inc.
    Inventors: Yusuke Nakamura, Yataro Daigo, Takuya Tsunoda, Ryuji Ohsawa, Sachiko Yoshimura, Tomohisa Watanabe
  • Patent number: 8182997
    Abstract: The present invention provides methods for detecting and diagnosing cancer, which method involves the determination of the expression level of the STYK1 gene. The gene was discovered to discriminate cancer cells from normal cells. Furthermore, the present invention provides methods of screening for therapeutic agents useful in the treatment of cancer, methods for treating cancer, and methods for vaccinating a subject against cancer. Moreover, the present invention provides siRNAs targeting the STYK1 gene, which are suggested to be useful in the treatment of cancer.
    Type: Grant
    Filed: August 8, 2007
    Date of Patent: May 22, 2012
    Assignee: Oncotherapy Science, Inc.
    Inventors: Yusuke Nakamura, Hidewaki Nakagawa, Shuichi Nakatsuru
  • Publication number: 20120107333
    Abstract: The present invention provides isolated peptides or the fragments derived from SEQ ID NO: 35, which bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL). The peptides may include one of the above mentioned amino acid sequences with substitution, deletion, or addition of one, two, or several amino acids sequences. The present invention also provides pharmaceutical compositions including these peptides. The peptides of this invention can be used for treating cancer.
    Type: Application
    Filed: March 1, 2010
    Publication date: May 3, 2012
    Applicant: Oncotherapy Science, Inc.
    Inventors: Takuya Tsunoda, Ryuji Ohsawa, Sachiko Yoshimura, Tomohisa Watanabe